Search - tctmd.com

Displaying 1 - 20 of 191

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Biggest News of 2025

Michael O'Riordan

January 01, 2026

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

Podcast Heart Sounds

Top Cardiology News for November 2025

November 25, 2025

News Daily News

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

Caitlin E. Cox

November 21, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

Presentation TCT 2025

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

Presenter: Hyun-Jong Lee

October 28, 2025

Presentation TCT 2025

TCT 59: Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Presenter: Jinying Zhou

October 28, 2025

Presentation TCT 2025

TCT 159: Effect of Evolocumab on coronary segments with calcified nodules: Insights from the YELLOW III study

Presenter: Pruthvi C. Revaiah

October 26, 2025

Presentation TCT 2025

Effect of EVOlocumab on Infarct Size in Patients with STEMI: The Prospective, Randomized, Open-Label EVO-STEMI Study

Presenter: Hyun-Jong Lee

October 25, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

Advertisement

TCTMD’s Biggest News of 2025

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Year in Review: Top Prevention Stories of 2025

December 2025 Dispatch for the CV Team

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

TCTMD’s Top 10 Most Popular Stories for November 2025

Top Cardiology News for November 2025

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

TCT 59: Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

TCT 159: Effect of Evolocumab on coronary segments with calcified nodules: Insights from the YELLOW III study

Effect of EVOlocumab on Infarct Size in Patients with STEMI: The Prospective, Randomized, Open-Label EVO-STEMI Study

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Evolocumab Gains Expanded Indication for Primary Prevention

What’s Going to Be Hot at ESC Congress 2025?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content